PRAME and diffuse large B-cell lymphoma: In aggregate, these data indicate that PRAME deletions are a genetically and clinically relevant CN alteration in GCB-DLBCL, which motivated us to perform further phenotypic and functional studies to elucidate potential oncogenic driver capacities.